Future of Allergen-Specific Immunotherapy: Better Understanding of the Mechanisms, Novel Treatments, and Long-Term Cure

Immunology and Allergy Clinics of North America

Volumn 26, Issue 2, 2006, Pages

  Akdis, Cezmi A ^a  

^a SWISS INSTITUTE OF ALLERGY AND ASTHMA RESEARCH SIAF   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ALLERGEN; ALUMINUM HYDROXIDE; ANTIBODY; ANTIGEN; BCG VACCINE; BEE VENOM; BIOLOGICAL MARKER; CYTOKINE; HISTAMINE; IMMUNOGLOBULIN A; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G4; IMMUNOLOGICAL ADJUVANT; OLIGODEOXYNUCLEOTIDE; PEPTIDE; PHOSPHOLIPASE A2; POLLEN ANTIGEN; POLYGLACTIN; RECOMBINANT VACCINE; VACCINE;

ALLERGIC DISEASE; ALLERGY; ANAPHYLAXIS; ANTIBODY PRODUCTION; CELLULAR IMMUNITY; CLINICAL PROTOCOL; CLINICAL TRIAL; DESENSITIZATION; DRUG ACTIVITY; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; EDITORIAL; EFFECTOR CELL; HISTAMINE RELEASE; HUMAN; IMMUNE RESPONSE; IMMUNOGLOBULIN PRODUCTION; IMMUNOLOGICAL PARAMETERS; IMMUNOREGULATION; IMMUNOTHERAPY; LONG TERM CARE; MUCOSA; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; SENSITIZATION; STANDARDIZATION; TH1 CELL; TH2 CELL;

ALLERGENS; DESENSITIZATION, IMMUNOLOGIC; HUMANS; HYPERSENSITIVITY; LONG-TERM CARE; VACCINATION;

EID: 33646412874     PISSN: 08898561     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.iac.2006.02.013     Document Type: Editorial

References (25)

1. Akdis C.A., Akdis M., Blesken T., et al. Epitope-specific T cell tolerance to phospholipase A2 in bee venom immunotherapy and recovery by IL-2 and IL-15 in vitro. J Clin Invest 98 7 (1996) 1676-1683
2. Akdis C.A., Blesken T., Akdis M., et al. Role of interleukin 10 in specific immunotherapy. J Clin Invest 102 1 (1998) 98-106
3. Jutel M., Akdis M., Budak F., et al. IL-10 and TGF-β cooperate in regulatory T cell response to mucosal allergens in normal immunity and specific immunotherapy. Eur J Immunol 33 (2003) 1205-1214
4. Francis J.N., Till S.J., and Durham S.R. Induction of IL-10+ CD4+ CD25+ T cells by grass pollen immunotherapy. J Allergy Clin Immunol 111 6 (2003) 1255-1261
5. Ling E.M., Smith T., Nguyen X.D., et al. Relation of CD4+ CD25+ regulatory T-cell suppression of allergen-driven T-cell activation to atopic status and expression of allergic disease. Lancet 363 9409 (2004) 608-615
6. Akdis M., Verhagen J., Taylor A., et al. Immune responses in healthy and allergic individuals are characterized by a fine balance between allergen-specific T regulatory 1 and T helper 2 cells. J Exp Med 199 11 (2004) 1567-1575
7. Akdis C.A., and Blaser K. Bypassing IgE and targeting T cells for specific immunotherapy of allergy. Trends Immunol 22 (2001) 175-178
8. Akdis M., Blaser K., and Akdis C.A. T regulatory cells in allergy: novel concepts in the pathogenesis, prevention, and treatment of allergic diseases. J Allergy Clin Immunol 116 5 (2005) 961-968
9. Akdis C.A., and Blaser K. Histamine in the immune regulation of allergic inflammation. J Allergy Clin Immunol 112 (2003) 15-22
10. Jutel M., Watanabe T., Klunker S., et al. Histamine regulates T-cell and antibody responses by differential expression of H1 and H2 receptors. Nature 413 6854 (2001) 420-425
11. Szeberenyi J.B., Pallinger E., Zsinko M., et al. Inhibition of effects of endogenously synthesized histamine disturbs in vitro human dendritic cell differentiation. Immunol Lett 76 3 (2001) 175-182
12. Akdis C.A., Blesken T., Wymann D., et al. Differential regulation of human T cell cytokine patterns and IgE and IgG4 responses by conformational antigen variants. Eur J Immunol 28 (1998) 914-925
13. 2 induces specific T-cell anergy in patients allergic to bee venom. J Allergy Clin Immunol 101 (1998) 747-754
14. Marcotte G.V., Braun C.M., Norman P.S., et al. Effects of peptide therapy on ex vivo T-cell responses. J Allergy Clin Immunol 101 4 Pt 1 (1998) 506-513
15. Oldfield W.L., Larche M., and Kay A.B. Effect of T-cell peptides derived from Fel d 1 on allergic reactions and cytokine production in patients sensitive to cats: a randomised controlled trial. Lancet 360 (2002) 47-53
16. Kussebi F., Karamloo F., Rhyner C., et al. A major allergen gene-fusion protein for potential usage in allergen-specific immunotherapy. J Allergy Clin Immunol 115 2 (2005) 323-329
17. Karamloo F., Schmid-Grendelmeier P., Kussebi F., et al. Prevention of allergy by a recombinant multi-allergen vaccine with reduced IgE binding and preserved T cell epitopes. Eur J Immunol 35 11 (2005) 3268-3276
18. Niederberger V., Horak F., Vrtala S., et al. Vaccination with genetically engineered allergens prevents progression of allergic disease. Proc Natl Acad Sci USA 101 Suppl 2 (2004) 14677-14682
19. Gafvelin G., Thunberg S., Kronqvist M., et al. Cytokine and antibody responses in birch-pollen-allergic patients treated with genetically modified derivatives of the major birch pollen allergen Bet v 1. Int Arch Allergy Immunol 138 1 (2005) 59-66
20. Jutel M., Jaeger L., Suck R., et al. Allergen-specific immunotherapy with recombinant grass pollen allergens. J Allergy Clin Immunol 116 3 (2005) 608-613
21. Akdis C.A., Kussebi F., Pulendran B., et al. Inhibition of T helper 2-type responses, IgE production and eosinophilia by synthetic lipopeptides. Eur J Immunol 33 10 (2003) 2717-2726
22. Simons F.E., Shikishima Y., Van Nest G., et al. Selective immune redirection in humans with ragweed allergy by injecting Amb a 1 linked to immunostimulatory DNA. J Allergy Clin Immunol 113 6 (2004) 1144-1151
23. Zhu D., Kepley C.L., Zhang K., et al. A chimeric human-cat fusion protein blocks cat-induced allergy. Nat Med 11 4 (2005) 446-449
24. Gronlund H., Vrtala S., Wiedermann U., et al. Carbohydrate-based particles: a new adjuvant for allergen-specific immunotherapy. Immunology 107 4 (2002) 523-529
25. Roth-Walter F., Scholl I., Untersmayr E., et al. Mucosal targeting of allergen-loaded microspheres by Aleuria aurantia lectin. Vaccine 23 21 (2005) 2703-2710